Replies to post #279502 on Avid Bioservices Inc (CDMO)

[revenue_monster]

The MSK comments regarding PS targeting hardly validate. "We believe" "potential" etc. validation can only come from human trials. i am sure MSK has said similar things about other drugs only to see them fall short.

[biopharm]

..According to Bishop, investigators pinpointed the likely culprit as the addition of fludarabine to the pre-conditioning regimen. Fludarabine is a chemotherapy drug used here as a one-time primer for treatment, used in an effort to increase the effectiveness of the experimental therapy.
...
...

So JUNO stopped using this primer drug, fludarabine.....and still trouble....so JUNO had a modified trial moving forward and with JUNO adviser Dr Jedd Wolchok, has he advised the use of Bavituximab or other PS Targeting drug??

We shall see.....since Dr Jedd Wolchok scheduled to speak Jan 2018 and JUNO likely one which could be used as how off target TOXICITIES can be reduced and footprint of patients can be increased....

We know Dr Jedd Wolchok already has seen the powers of no off target TOXICITIES with PS Targeting

The question still remains....why oh why has not Ronin group filed with SEC to legally keep PS Targeting collaborations active with NCCN MSK and yes, with Dr Jedd Wolchok